The shareholders of interventional device vendor Guidant have approved the firm's acquisition by Johnson & Johnson for $25.4 billion in fully diluted equity.
The agreement remains subject to European and U.S. regulatory review, as well as other customary closing conditions, according to Indianapolis-based Guidant.
By AuntMinnie.com staff writers
April 27, 2005
Related Reading
Guidant reports Q1 revenue growth, April 21, 2005
Verdicts come down in Medtronic/Guidant dispute, February 21, 2005
GE, Guidant offer free screenings, February 3, 2005
Guidant reports record year, January 27, 2005
Court issues judgment in stent patent dispute, January 6, 2005
Copyright © 2005 AuntMinnie.com
